# US 5,705,162 A · FeLV therapeutic agent, method of its preparation, and method of treating FeLV infection therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,162 A
- Document ID: US5705162A
- Status: Granted
- Kind: A
- Application number: 08/543,820
- Filed: 1995-10-16
- Granted: 1998-01-06
- Earliest claimed: 1995-10-16
- Assignees: Parhelion Corporation
- Inventors: Richard G. Olsen; John L. Ridihalgh
- Web page: https://patentgrep.com/patent/US5705162A

## CPC

- A61K 35/26: Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- C12N 5/0651: {Lymph nodes}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- C12N 2501/23: Interleukins [IL]
- Y10S 424/819: Viral vaccine for feline species, e.g. cats
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention broadly relates to a therapeutic agent effective in mitigating disease associated with Feline Leukemia Virus (FeLV) in a feline infected with FeLV. A feline is an animal of the family Felidae. The novel therapeutic agent is composed of feline excised lymph nodes which have been subjected to mitogenic stimulation for their expansion dispersed in a pharmaceutically-acceptable carrier. Mitogenic stimulation conditions include culturing the excised lymph nodes in the presence of Interleukin-2. Optionally, culture conditions can include the presence of allogeneic or autologous FeLV tumor. The inventive therapeutic agent is prepared by excising lymph nodes from a feline infected the FeLV, mitogenically stimulating said excised lymph nodes for their expansion, and administering to the infected feline the expanded lymph nodes. Multidose regimens can be used as is necessary or desirable in convenient fashion. The method for mitigating disease associated with Feline Leukemia Virus (FeLV) in a feline infected with FeLV is composed of administering to the diseased feline the therapeutic agent composed of feline excised lymph nodes which have been subjected to mitogenic stimulation for their expansion dispersed in a pharmaceutically-acceptable carrier.

## Claims

### Claim 1

A method for mitigating disease associated with Feline Leukemia Virus (FeLV) in a feline infected with FeLV, which comprises administering to said feline an effective amount of a therapeutic agent comprising lymph node lymphocytes (LNL) expressed from excised lymph nodes taken from an FeLV-infected feline in which said LNL have been subject to mitogenic stimulation by their culturing in the presence of Interleukin-2 for their expansion.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of Interleukin-2 ranges from between about 10 and 500 u/ml.

### Claim 3 (depends on 1)

The method of claim 1, wherein said culturing further includes FeLV infected cells.

### Claim 4 (depends on 3)

The method of claim 3, wherein said FeLV infected cells were inactivated prior to their culturing with said lymph node lymphocytes.

### Claim 5 (depends on 4)

The method of claim 4, wherein said FeLV infected cells were heated for inactivation.

### Claim 6 (depends on 1)

The method of claim 1, wherein said therapeutic agent is administered more than one time with a suitable time period elapsing between said administering.

### Claim 7 (depends on 2)

The method of claim 2, wherein said therapeutic agent is administered more than one time with a suitable time period elapsing between said administering.

### Claim 8 (depends on 3)

The method of claim 3, wherein said therapeutic agent is administered more than one time with a suitable time period elapsing between said administering.

### Claim 9 (depends on 4)

The method of claim 4, wherein said therapeutic agent is administered more than one time with a suitable time period elapsing between said administering.

### Claim 10 (depends on 5)

The method of claim 5, wherein said therapeutic agent is administered more than one time with a suitable time period elapsing between said administering.